COVID-19 Year Two: Looking Back/Looking Forward

Life Sciences MoForum

20 May 2021 12:00 p.m. - 01:30 p.m. EDT

We welcomed 200+ attendees to our inaugural Life Sciences MoForum on COVID-19 Year Two: Looking Back/Looking Forward, a panel discussion with Survivor Corps and Hugo Health moderated by Morrison & Foerster's Life Sciences Transactions + Licensing Group. We look forward to our next MoForum. Topics during this virtual program included:

  • COVID-19 Year Two – lessons learned, mistakes made, and where we go from here.
  • COVID-19 Variants – what are they, where did they come from, and should we be worried?
  • The COVID-19 Experience – understanding symptoms and why the virus affects people differently.
  • The Worldwide Vaccine Rollout – how has COVID-19 impacted drug development, manufacturing, and distribution? What are the key regulatory issues companies have faced in developing therapeutics and vaccines to address COVID-19?
  • The Future of Drug Development – what does the future look like for the development of drugs to treat and cure disease? What are the critical considerations for collaborations between and among companies, universities, non-profits, foundations, governments, and other key players in addressing viral threats?
  • The COVID-19 Response – lessons learned in facing a worldwide viral threat.


Matthew Karlyn, life sciences transactions + licensing partner at Morrison & Foerster LLP with over 25 years of experience in working with companies in the healthcare, pharmaceutical, medical device, and technology industries on a wide range of commercial life sciences, licensing, and technology transactions.


  • Diana Berrent, founder of Survivor Corps, a grassroots solution-based movement to mobilize those affected by COVID-19 to come together, participate in medical and scientific research, and take a more active role in trying to mitigate this pandemic;
  • Dr. Harlan Krumholz, cardiologist and scientist at Yale University and Yale New Haven Hospital and co-founder of Hugo Health, a patient-centric platform to engage people as partners in research and facilitate the secure movement of digital health data; and
  • Dr. Elizabeth (Liz) Newman, scientific analyst at Morrison & Foerster LLP with a Ph.D. in microbiology and immunology from New York Medical College, where she studied antibody responses to influenza and concentrated on viral genomics and vaccine design.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.